VIDEO: EYP-1901 shows consistent safety results at 8 months

ByJay S. Duker, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In this Healio Video Perspective, Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, discusses EYP-1901 for the treatment of wet age-related macular degeneration.

Duker shares an update on efficacy and safety data from the phase 1 DAVIO trial, presented at Angiogenesis, Exudation, and Degeneration 2022.

Published by:

Sources/Disclosures

Collapse

Source:

Jay S. Duker, MD

Read more about

gene therapy

wet age-related macular degeneration

visual acuity

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment